Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07828548

Effect of the Ansileve Supplement on the Well-being of Parents of Children Who Have Experienced a Medical Emergency: A Randomized Controlled Study

The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether the dietary supplement Ansileve (Ansileve SOS spray and Ansileve capsules) can improve psychological well-being and parental functioning in mothers and fathers of children experiencing an acute medical event requiring hospital care.

The main questions are:

1. Does acute administration of Ansileve SOS spray improve maternal functioning in the short term, as measured by the Barkin Index of Maternal Functioning (BIMF), compared with placebo? 2. Does Ansileve SOS spray and the subsequent 30-day supplementation with Ansileve capsules reduce anxiety symptoms and improve emotional well-being in parents, compared with placebo?

Researchers will compare participants receiving Ansileve SOS spray and/or Ansileve capsules with participants receiving matching placebo products to determine whether the intervention improves parental functioning, reduces anxiety symptoms, and supports psychological recovery after a stressful event involving their child.

Participants will:

* Be mothers and fathers (≥18 years) of children admitted for an acute medical event at the Pediatria Immunoreumatologia Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico * Complete validated questionnaires assessing functioning (BIMF, only mothers), emotional impact of the event [Impact of Event Scale - Revised (IES-R)], and anxiety symptoms [Generalized Anxiety Disorder Scale (GAD-7)] at baseline and during follow-up * Receive either Ansileve SOS spray or placebo spray at study enrolment. * Take either Ansileve capsules or placebo capsules daily for 30 days according to the assigned treatment group * Complete a follow-up assessment to evaluate treatment adherence and possible adverse events.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mothers and fathers of children presenting to the Pediatria Immunoreumatologia Unit of the De Marchi Pediatric Clinic for an acute medical event
  • Age ≥18 years
  • Provision of written informed consent

Exclusion criteria

  • Known psychiatric disorders
  • Failure to provide written informed consent
  • Insufficient proficiency in the Italian language
  • Pregnancy or breastfeeding
  • Known allergy or intolerance to one or more components of the food supplement

Treatment and study plan

Ansileve SOS Spray

Dietary Supplement

Dietary supplement in spray containing Ashwagandha, Hawthorn, Hemp seed oil, and Lavender, known to promote relaxation and support emotional balance. It will be administered as 4 sprays under the tongue, three times daily.

Ansileve

Dietary Supplement

Dietary supplement in capsule form combining plant extracts of Melissa officinalis and Griffonia simplicifolia, B-group vitamins, and hydrolyzed marine peptides. Two capsules will be administered daily, away from meals.

Primary outcomes

  1. Effect of the spray treatment (Ansileve SOS Spray vs placebo spray) on maternal functioning.

    Time frame: From baseline (T0) to 30 minutes after spray administration (T1).

    Change in maternal functioning after spray administration, measured by the change in BIMF questionnaire score, comparing the Ansileve SOS Spray group with the placebo spray group.

Secondary outcomes

  1. Short-term change in emotional impact and anxiety symptoms after Ansileve SOS Spray in parents.

    Time frame: From baseline (T0) to 30 minutes after spray administration (T1).

    Comparison of changes in scores for the emotional impact of the traumatic event and anxiety symptoms between Ansileve SOS Spray and placebo groups, measured using validated questionnaires (IES-R and GAD-7).

  2. Long-Term Effects of Ansileve Capsules on Anxiety Symptoms in Parents.

    Time frame: From 30 minutes after spray administration (T1) to 30 days after capsule administration (T2).

    Comparison of changes in GAD-7 anxiety scores after capsule administration between the Ansileve capsule group and the placebo capsule group.

  3. Combined effects of Ansileve SOS Spray and Ansileve capsules on anxiety symptoms in parents

    Time frame: From 30 minutes after spray administration (T1) to 30 days after capsule administration (T2).

    Evaluation of the combined effect of Ansileve SOS Spray and Ansileve capsules on anxiety symptoms by comparing changes in GAD-7 scores between the active combination group and the placebo group.

Study contacts

Contact information is provided by the study sponsor or research team.

Cristiana Berti

CONTACT

[email protected]

+39 02 55034338

Silvia Bettocchi

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Other

Collaborators

  • Fondazione De Marchi
  • University of Calabria
  • University of Milan

Registry information

Official study title

Effetto Dell'Integratore Ansileve Sul Funzionamento Genitoriale in Soggetti Esposti a un Evento Emergenziale Per il Bambino: Studio Randomizzato Controllato

Acronym: ParentSOS

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 18, 2026
Registry last updated
Sep 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.